This is a routine administrative amendment with no change in position or intent. Monitor for any future 13D amendments that signal a change in strategy, such as increasing the blocker limit or engaging in transactions.
FATE drugs
FATE drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 10 $1.77entry
- T+1 · 6d ago −9.32%α −10.64% · $1.61
- T+4 · todayOpen
- T+5 · in 5h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Redmile Group filed Amendment No. 11 to its Schedule 13D solely to add Redmile Capital Offshore II Master Fund, Ltd. as a reporting person after its beneficial ownership surpassed 5% due to a change in Fate Therapeutics' outstanding share count. No transactions were executed, the aggregate stake remains at 14.99% (19,164,572 shares deemed beneficially owned), and no new demands or changes in purpose were disclosed.
Key Financial Metrics
Key Facts
- Redmile Group and related entities collectively own 19,164,572 shares of Fate Therapeutics, representing 14.99% of common stock.
- Redmile Capital Offshore II Master Fund, Ltd. was added as a reporting person after its beneficial ownership crossed 5% due to a change in the issuer's outstanding share count.
- No transactions were executed by the reporting persons since the prior filing (Amendment No. 10 on April 22, 2026).
- The filing states the purpose is unchanged; no new demands, strategic review, or board representation requests were disclosed.
- The stake is subject to beneficial ownership blockers limiting conversion/exercise to 14.99% (can be increased to 19.99% with 61 days' notice).
Financial Impact
No financial impact; stake unchanged at 14.99% of shares outstanding.
Risk Factors
- Redmile holds significant convertible preferred stock and pre-funded warrants that, if converted/exercised, could increase dilution but are currently capped at 14.99% beneficial ownership.
- The blocker can be raised to 19.99% with 61 days' notice, which would signal increased conviction or potential activism.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13D/A Filing (Primary) | 0000905148-26-004718 |
| Document: 0000905148-26-004718-index-headers.html | 0000905148-26-004718 |
| Document: 0000905148-26-004718-index.html | 0000905148-26-004718 |
| Document: 0000905148-26-004718.txt | 0000905148-26-004718 |
Track record
21 reports on FATE
4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +30.25% at T+5 after the Nov 5, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 13, 20264d ago EFFECT Bearish 5/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
- Nov 12, 20264d ago 424B5 Bearish 4/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
- Nov 9, 20267d ago SC 13D/A Neutral 2/10 Viewing Entry $1.77 Now $1.14 −35.59% settles Nov 17
- Nov 5, 202611d ago S-3 Neutral 3/10 Entry $1.84 to $1.28 Now $1.14 −37.87% ▼ −30.25% −32.84% vs SPY
- Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.85 to $1.34 Now $1.14 −38.38% ▼ −27.57% −30.86% vs SPY
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $2.09 to $1.61 Now $1.14 −45.45% ▼ −23.21% −22.29% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $2.04 to $1.77 Now $1.14 −44.12% ▼ −13.24% −12.65% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers